🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

60,88 USD

Máx. histórico

89,55

116 días

Caída desde máximo

-32,02%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,52%

Cierre anterior

59,97

Rango de hoy

59,16 – 62,16

Volumen hoy

1.334.171

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,93%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,40 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 22 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/12/2025 75,96 76,98 75,59 75,96 -0,30% 1,83% 961.800
30/12/2025 77,29 77,93 75,58 76,19 -1,87% 3,04% 679.500
29/12/2025 78,20 78,67 77,08 77,64 -1,17% 2,03% 1.000.100
26/12/2025 78,32 78,72 77,45 78,56 +0,24% 1,62% 525.600
24/12/2025 77,83 78,91 77,18 78,37 +0,86% 2,22% 308.200
23/12/2025 78,59 79,46 77,26 77,70 -1,52% 2,80% 712.000
22/12/2025 78,14 80,20 78,14 78,90 +0,42% 2,64% 1.314.700
19/12/2025 75,29 79,31 74,57 78,57 +5,34% 6,30% 2.741.200
18/12/2025 75,48 75,48 73,78 74,59 -0,47% 2,25% 1.391.200
17/12/2025 75,38 76,17 74,18 74,94 -0,64% 2,64% 960.900
16/12/2025 75,46 76,14 74,17 75,42 -1,09% 2,60% 1.302.200
15/12/2025 76,00 77,38 75,14 76,25 +0,81% 2,95% 1.525.200
12/12/2025 75,83 76,16 74,50 75,64 +0,27% 2,19% 941.300
11/12/2025 74,23 75,98 73,96 75,44 +1,81% 2,72% 723.000
10/12/2025 73,87 75,62 73,44 74,10 +0,86% 2,95% 1.184.500
09/12/2025 76,53 76,95 73,09 73,47 -4,47% 5,04% 1.295.500
08/12/2025 77,58 78,77 76,63 76,91 -0,45% 2,76% 1.086.600
05/12/2025 77,92 78,68 76,54 77,26 -0,76% 2,75% 848.400
04/12/2025 74,83 79,03 74,83 77,85 +2,76% 5,61% 1.615.800
03/12/2025 78,62 78,66 73,03 75,76 -3,48% 7,15% 2.495.900
02/12/2025 79,66 80,51 77,87 78,50 -0,89% 3,32% 2.305.200
01/12/2025 83,19 84,06 78,89 79,20 -7,90% 6,21% 2.896.900
28/11/2025 86,21 86,76 84,82 85,99 -0,30% 2,25% 1.109.600
26/11/2025 83,32 87,50 82,84 86,25 +4,00% 5,59% 15.474.700
25/11/2025 84,69 85,62 81,89 82,93 +3,88% 4,40% 4.288.500
24/11/2025 79,09 81,16 78,97 79,83 +1,73% 2,77% 1.174.200
21/11/2025 76,54 79,98 75,34 78,47 +2,63% 6,06% 1.333.200
20/11/2025 76,95 78,74 75,90 76,46 +1,14% 3,70% 1.479.800
19/11/2025 76,37 76,89 75,52 75,60 -1,42% 1,79% 1.022.900
18/11/2025 75,04 77,46 74,02 76,69 +1,44% 4,58% 978.900